Table 3. HR and 95% CI for lung cancer according to serum bilirubin levelsa.
| Men | Women | |||||||||
| PY | Lung cancer | Rate per 10,000 | HR (95% CI)b | HR (95% CI) | PY | Lung cancer | Rate per 10,000 | HR (95% CI)b | HR (95% CI) | |
| Bilirubin level (mg/dl) | ||||||||||
| T3 | 122109.6 | 32 | 2.6 | 1.0 | 1.0 | 101483.9 | 19 | 1.9 | 1.0 | 1.0 |
| T2 | 81282.7 | 45 | 5.5 | 1.8 (1.2–2.9) | 1.9 (1.2–3.0) | 96530.8 | 18 | 1.9 | 0.9 (0.5–1.7) | 0.9 (0.5–1.7) |
| T1 | 116718.1 | 104 | 8.9 | 2.5 (1.7–3.7) | 2.8 (1.8–4.2) | 98304.0 | 22 | 2.2 | 1.0 (0.5–1.9) | 1.0 (0.5–1.9) |
| P for trend | 0.0007 | <0.0001 | 0.5006 | 0.5964 | ||||||
| 1SD increase | 0.7 (0.5–0.8) | 0.6 (0.5–0.8) | 1.0 (0.8–1.3) | 1.0 (0.8–1.3) | ||||||
| 1 mg/dl increase | 0.3 (0.2–0.5) | 0.2 (0.1–0.4) | 1.0 (0.4–2.7) | 1.0 (0.4–2.6) | ||||||
a
Adjusted for age, body mass index, white blood cell count, hemoglobin, and alcohol intake.
b
Additionally adjusted for smoking status.
Abbreviation: PY, person year; SD, standard deviation; T3, highest tertile; T2, middle tertile; T1, lowest tertile.